Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study

Table 2

RA descriptors.

	Overall	ED	No ED	value
Disease duration (months)	131.8 ± 116	141.1 ± 116	127 ± 115	ns
ACPA positivity (%)	62.8	55.9	66.2	0.009
IgM-RF positivity (%)	67	62.8	69	ns
ESR (mm/h)	26.4 ± 20	25.9 ± 21	26.7 ± 20	ns
CRP (mg/dL)	0.59 ± 0.9	0.56 ± 0.7	0.61 ± 0.9	ns
DAS-28	3.53 ± 1.3	3.51 ± 1.2	3.52 ± 1.3	ns
HAQ	0.75 ± 0.6	0.79 ± 0.7	0.73 ± 0.6	ns
Steroid use (%)	37.6	38.4	37.2	ns
Steroid dose (mg/day)	2.9 ± 3.9	3 ± 4.6	2.8 ± 3.6	ns
Cumulative steroid dose (mg/month)	87 ± 119	91.2 ± 139	84.9 ± 108	ns
NSAID use (%)	23.4	25.1	22.6	ns
DMARD use (%)	78.6	78.8	78.5	ns
TNFi use (%)	28.7	29.1	28.5	ns
Tocilizumab use (%)	7.2	7.2	7.1	ns
Abatacept use (%)	5.1	5.1	5.1	ns
Rituximab use (%)	2.4	2.4	2.4	ns

ns: not significant.